News - SAb Biotherapeutics

April 21, 2021

SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial

Part of NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-2) master protocol Trials are funded, sponsored and conducted by Department…

RSS

SAB Biotherapeutics Strengthens Senior Management Team with Appointment of Kipp Erickson, PhD as Chief Operating Officer

April 13, 2021

SAB Biotherapeutics to Present at Upcoming March Investor Conferences

March 4, 2021

SAB Biotherapeutics Announces New Appointments to its Board of Directors

December 15, 2020

SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19

November 30, 2020

SAB Biotherapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of SAB-185 For The Treatment Of COVID-19

August 21, 2020

SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-185 For The Treatment And Prevention Of COVID-19

August 11, 2020

SAB Biotherapeutics Awarded $35.6M From U.S. Department Of Defense For COVID-19 And Scaling Rapid Response Antibody Program

August 6, 2020

SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-176 For Seasonal Influenza

July 30, 2020

SAB Biotherapeutics Closes Series B Funding

July 17, 2020

Cows Help With COVID-19 Treatment, No Bull

June 17, 2020

Human Trials Expected To Start Next Month For Covid-19 Treatment Derived From Cows’ Blood

June 16, 2020